Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Treen C M Morris

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Leukemia & Lymphoma|December 30, 2009
Thalidomide-induced phrenic nerve paralysisAbdulhakim Eswedi, Philip Burnside, Treen C M Morris
The Lancet. Oncology|November 4, 2006
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myelomaKhaled M A Ramadan, Kevin E McKenna, Treen C M Morris
British Journal of Haematology|June 17, 2004
Bone marrow architecture in acute myeloid/erythroid leukaemiaScott M McCloskey, Mary F McMullin, Treen C M Morris, et al.
Journal of Leukocyte Biology|July 21, 2010
Adiponectin is produced by lymphocytes and is a negative regulator of granulopoiesisLisa J A Crawford, Roy Peake, Susan Price, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 30, 2004
Novel uses for recombinant erythropoietin therapy in unlicensed indicationsChristine A Macartney, A A Jennifer Adgey, Frank G C Jones, et al.
Cancer Research|June 17, 2006
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132Lisa J A Crawford, Brian Walker, Huib Ovaa, et al.
British Journal of Haematology|May 25, 2002
The endogenous granulocyte colony-stimulating factor response following autologous peripheral blood stem cell transplantation is impaired in patients with myelomaTreen C M Morris, Margaret K Magill, Mary Drake, et al.
British Journal of Haematology|September 17, 2013
Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) TrialTreen C M Morris, Cathy Williams, Sue Bell, et al.
Bone Marrow Transplantation|June 29, 2022
Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory studyJohn A Snowden, Sam H Ahmedzai, Angela Cox, et al.
Bone Marrow Transplantation|January 10, 2024
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trialRuth M de Tute, Gordon Cook, David A Cairns, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Leukemia & Lymphoma|December 30, 2009
Thalidomide-induced phrenic nerve paralysisAbdulhakim Eswedi, Philip Burnside, Treen C M Morris
The Lancet. Oncology|November 4, 2006
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myelomaKhaled M A Ramadan, Kevin E McKenna, Treen C M Morris
British Journal of Haematology|June 17, 2004
Bone marrow architecture in acute myeloid/erythroid leukaemiaScott M McCloskey, Mary F McMullin, Treen C M Morris, et al.
Journal of Leukocyte Biology|July 21, 2010
Adiponectin is produced by lymphocytes and is a negative regulator of granulopoiesisLisa J A Crawford, Roy Peake, Susan Price, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 30, 2004
Novel uses for recombinant erythropoietin therapy in unlicensed indicationsChristine A Macartney, A A Jennifer Adgey, Frank G C Jones, et al.
Cancer Research|June 17, 2006
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132Lisa J A Crawford, Brian Walker, Huib Ovaa, et al.
British Journal of Haematology|May 25, 2002
The endogenous granulocyte colony-stimulating factor response following autologous peripheral blood stem cell transplantation is impaired in patients with myelomaTreen C M Morris, Margaret K Magill, Mary Drake, et al.
British Journal of Haematology|September 17, 2013
Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) TrialTreen C M Morris, Cathy Williams, Sue Bell, et al.
Bone Marrow Transplantation|June 29, 2022
Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory studyJohn A Snowden, Sam H Ahmedzai, Angela Cox, et al.
Bone Marrow Transplantation|January 10, 2024
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trialRuth M de Tute, Gordon Cook, David A Cairns, et al.
Pageof 2